Intissar Akalay

Intissar Akalay, Ph.D. has over 15 years of work experience in the field of oncology research. Intissar is currently employed as the Head of Laboratory and Principal Scientist at Boehringer Ingelheim, where they are responsible for developing translational strategies and identifying biomarkers for various oncology programs. Prior to this, they worked as a Senior Scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson, Memorial Sloan Kettering Cancer Center, and MD Anderson Cancer Center, where they focused on developing novel therapeutic approaches and investigating tumor suppressors' roles in preventing tumor invasion and metastases. Intissar also conducted postdoctoral research at Memorial Sloan Kettering Cancer Center and Gustave Roussy, where they studied the impact of Epithelial to Mesenchymal Transition (EMT) on cancer immune surveillance and identified predictive and prognostic biomarkers for invasion and metastasis in patients with melanoma. Intissar Akalay's diverse research experience demonstrates their expertise in oncology and translational sciences.

Intissar Akalay, Ph.D. earned their first Master's degree in Cell Biology from the School of Pharmacy at Reims Champagne-Ardennes University in 2007. Intissar then pursued a second Master's degree in Oncology: Pharmacology and Therapeutics from the School of Medicine La Timone at Aix-Marseille University, completing it in 2008. Akalay went on to achieve a Doctor of Philosophy (Ph.D.) in Immuno-oncology from the School of Medicine at Paris XI University, which they completed in 2013.